A Bright Future In IHC

Seven Novel IHC Markers — Now Available

Your commitment to patient health continues to inspire the expansion of our IHC offerings. Thanks to your dedication to advanced staining, we are pleased to announce the latest additions to the Cell Marque™ IHC testing portfolio: ATRX (polyclonal), PAX-8 (SP348), Peripherin (8G2), SMAD4 (MRQ-72), Somatostatin Receptor 2A (EP149), and Tyrosine Hydroxylase (LNC1).

ATRX
ATRX (Polyclonal)
Learn More
PAX8
PAX-8 (SP348)
Learn More
Peripherin
Peripherin (8G2)
Learn More
PRAME (EP461)
PRAME (EP461)
Learn More
Somatostatin Receptor 2A (EP149)
Somatostatin Receptor 2A (EP149)
Learn More
Tyrosine Hydroxylase
Tyrosine Hydroxylase (LNC1)
Learn More
SMAD4
SMAD4 (MRQ-72)
Learn More

2023 NSH Convention

Save the Date – We’re Waiting for You!

Are you ready for the latest Histotechnology courses, exciting vendor visits, and virtual poster sessions at NSH 2023? So are we!

Visit us September 10-12 in Baltimore at Booth #206. When you visit our booth, you can chat with tissue diagnostics experts Cell Marque™ IHC technical consultants and get your hands on our Midas® III-Plus Automated Stainer. We can’t wait to see you there.

Some topics we are excited about:

  • Newly Released IHC Antibodies
  • Midas® III-Plus Automated Stainer
  • Special and Routine Stains
  • Cell Line Controls
  • Purified Antibodies for Spatial Biology
  • ATRX, IDH1, SMAD4, PRAME, and more!

Be Somebody’s Hero with Pediatric IHC Markers  

Be Somebody’s Hero with Pediatric IHC Markers  

We know that childhood cancer is relatively rare overall. In honor of Pediatric Cancer Awareness Month, we strive to shine a light on the heroic measures taken in histopathology. An estimated 400,000+ children will be diagnosed with some form of cancer worldwide each year. Survival rates have increased in recent decades due in part to early and accurate detection and advancements in treatment. Your heroic efforts in the lab inspire us and continue to help save lives every day.

From a histological perspective, pediatric cancers under the microscope can be quite varied in appearance, and their detection may require more focused immunohistochemistry and ancillary testing. Because of this, and the rapid growth of some forms of pediatric cancer, accurate and timely detection is a valuable secret weapon. 

We offer a robust portfolio of pediatric markers for IHC, including sensitive and specific rabbit monoclonal options. 

Top Pediatric Markers: 

PAX-7

Peripherin

Tyrosine Hydroxylase

PHOX2B

CITED1

NKX2.2 

Pediatric Pathology Portfolio

USCAP 2023 – New Orleans, LA

Save the Date – We’re Waiting for You!

Are you gearing up for the latest pathology courses, exciting vendor visits, and innovative poster sessions at USCAP? So are we!

Visit us March 13-15 in New Orleans at Booth #558. Monday and Tuesday from 1pm-4pm, join us for an interactive caricature experience where we will transform our visitors into pathology heroes! You don’t want to miss the fun.

When you visit our booth, you can chat with Cell Marque™ IHC experts, including our two in-house pathologists, technical consultants, and R&D scientists!

Some topics we are excited about:

  • Newly Released IHC Antibodies
  • Antibody Pipeline
  • Cell Line Controls
  • Quality and Performance
  • IHC Flashcards
  • ATRX, IDH1, SMAD4, PRAME, and more!

Trilogy® Pretreatment Solution – A Newer Formulation

New Formulation, Same Great Pretreatment

Designed for quality and efficiency, formulated for a greener Earth.

With standards in laboratory sustainability on the rise, we strive to offer innovative solutions for your IHC processes. Our efficient and now greener alternative to conventional EDTA pretreatments offers exactly that. While the new formulation may have new part numbers, it remains gentle on tissue while possessing the strong unmasking capabilities you have come to expect from the Trilogy® solution.

Benefits of Trilogy® Pretreatment Solution

Quality: Customer-preferred pretreatment for their antibodies based on stronger results obtained

Cost: Outstanding unmasking ability leads to higher titers, resulting in more efficient use of antibodies

Versatility: Three-in-one retrieval solution; deparaffinizing, rehydrating, and unmasking all in one step

Time: Pretreatment step can be completed in a quicker, 15–35-minute procedure

Standardization: Standardizes pretreatment protocols, increasing the efficiency of the lab

Study Abroad: 2022 Webinar Series

Attention Passengers:

Are you ready for another adventure in IHC education?

This summer, we will embark on a 6-week free webinar series, so get your virtual bags packed and fasten your seatbelts for the webinar adventure of the year.

As you navigate the HistoHero seas, your trusty Tissue Diagnostics “Pilots” will take you to 6 weekly destinations. Each hour-long session will offer NSH CE credits upon completion. The full itinerary for our Study Abroad: 2022 Webinar Series is still in development. Don’t miss a single announcement.

Interested in taking the journey with us this year?

Register Now

New IVD Trio for Prostate

These 3 markers have been vital for prostate testing for years. As valuable antibodies to aid in differentiating prostate diagnoses, we understand the importance of having them making them available as IVD for IHC labs around the world. Today, p40, p63, and P504s are officially available as IVD from your trusted partners in IHC.

The Cell Marque™ IHC Antibody Portfolio offers a variety of valuable and reliable markers for your prostate testing. Request a quote or order a sample size today and see the difference for yourself!


p40

p40 (ZR8)
Rabbit Monoclonal Antibody
Learn More

p63

p63 (EP174)
Rabbit Monoclonal Primary Antibody
Learn More

p504s

P504s (13H4)
Rabbit Monoclonal Antibody
Learn More

PRAME (EP461) Rabbit Monoclonal Antibody – Available Now!

Add the newest melanoma marker to your dermatopathology staining today! 

Skin cancer is the most diagnosed neoplasm globally, by far. Although most skin cancer cases like basal cell carcinoma and squamous cell carcinoma do not typically require immunostaining, melanoma diagnosis utilizes immunohistochemistry routinely. PRAME is a melanoma antigen that is preferentially expressed in tumors and is recognized by cytotoxic T lymphocytes.  

PRAME can be used to distinguish between malignant melanoma cells and nevus cells, and therefore may be useful for diagnostic purposes to support a suspected case of melanoma.

View Product

Benefits of PRAME:

  • For in vitro diagnostic use  
  • Nuclear visualization to eliminate cytoplasmic melanin interference  
  • Rabbit monoclonal technology for robust staining and minimal background 
  • Differentiates malignant melanocytes from dysplastic and nodal nevi 
  • May also differentiate malignant peripheral nerve sheath tumors from benign peripheral nerve sheath tumors
  • Compatible with standard automation and detection used in diagnostic IHC

    Request a Quote

IDH1 R132H for Subtyping and Differentiation of Neuropathology Applications

The wait is over – IDH1 R132H is Now Available Worldwide! Additionally, current users can now expand their IVD IDH1 testing to include applications surrounding brain cancer!  This reliable IHC antibody aids in the identification of anaplastic astrocytoma, oligodendrogliomas, and secondary glioblastomas.

View Product

Benefits of IDH1 R132H:

  • For in vitro diagnostic use  
  • R132H mutant aids in differentiating grade II and grade III gliomas from reactive gliosis  
  • IDH1 R132H helps differentiate IDH1+ glioblastoma (oligodendroglial component) from IDH1- glioblastoma (small cell component)  
  • Detects IDH1 R132H mutations in acute myeloid leukemia.  
  • Compares favorably to existing mouse monoclonal versions of IDH1 R132H  
  • Exclusive IVD designation for neural tumor applications in the United States  

Learn More